Pharmetheus https://validator.w3.org/feed/docs/rss2.html Careers Protected: Advancing Cryptococcal Meningoencephalitis Treatment with Model-Informed Drug Development “My initial impressions of Pharmetheus turned out to be entirely true.“

 News Home Pharmetheus at PAGE 2025 Population modeling experts & PBPK and/or QSP modeling experts Protected: PBPK/PBBM services Academic collaborations History of Pharmetheus Protected: Quantitative Systems Pharmacology (QSP) Protected: QSP services Protected: Workshop archive Working with us Protected: PBPK/PBBM Karam Alali shares his experience of Uppsala Pharmacometric Summer School Protected: Forest plots in practical use: Implementation and interpretation Lisa Sundin Good health and well-being Integrated modeling of biomarkers, survival and safety in clinical oncology drug development Workshop: Learn and apply TTE and RTTE modeling with a focus on NONMEM Workshop: PBPK Modeling for First-in-Human & DDI with OSP Suite Symposium: MIDD in regulatory interactions – Practical takes on the Draft ICH M15 Guideline Speed advising for students Events Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria New publication on crovalimab’s pharmacokinetics and exposure–response in PNH trials Benjamin Weber MIDD and pharmacology conferences we are attending in 2025 Sofia Friberg Hietala Sven Alfredsson Lena Lindeberg Elodie Plan Joakim Nyberg Mats Magnusson Mikael Haglund Emma Ångström Marylore Chenel Peter Wilén Anjali Menon Karen Watson “Values are not just external slogans, they need to be lived” Registration and Purchase Terms, workshops and events Emma Hansson Subcutaneous drug delivery: PBPK-QSP model for absorption and anti-drug antibody response Harriet Mellenius Chun Liu A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol and Caffeine [2] A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine [1] Pharmacometrics